Stay updated with breaking news from Code Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
By Colin Kellaher TransCode Therapeutics shares fell sharply on Thursday after the RNA oncology company filed with the U.S. Securities and Exchange...
By Josh Beckerman TransCode Therapeutics shares were recently down 49% to $1.10 after the pricing of a $7.25 million public offering. Shares fell to a...